ArticleFrontiers in immunology2026
Serum RNASE1 as a biomarker for disease activity and lupus nephritis in systemic lupus erythematosus.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease characterized by autoantibody production and immune complex-mediated organ damage, frequently involving the kidneys as lupus nephritis (LN). However, reliable blood-based biomarkers for disease activity and renal involvement remain limited. Methods: We performed serum proteomic profiling in newly diagnosed SLE patients and integrated these data with renal transcriptomic datasets from SLE mouse models to identify candidate biomarkers. Associations between serum RNASE1 levels and clinical parameters were evaluated, and a composite RNASE1-albumin-calcium (RAC) score was developed. Results: RNASE1 was consistently upregulated in both serum and renal tissues of SLE patients. Serum RNASE1 levels were significantly elevated compared with healthy controls and showed positive correlations with proteinuria and SLE Disease Activity Index (SLEDAI) scores, and a negative correlation with complement C3. The RAC score demonstrated stronger correlations with disease activity and renal function than RNASE1 alone. Receiver operating characteristic (ROC) analysis showed that the RAC score discriminated SLE disease activity with area under the curve (AUC) values of 0.7654, 0.7737, and 0.8072 for ≥mild, ≥moderate, and ≥severe activity, respectively. In addition, renal RNASE1 expression increased with LN severity and was significantly higher in class IV ± V LN than in class III ± V or class V LN, correlating with the pathological activity index. Discussion: RNASE1 is a promising biomarker reflecting both systemic disease activity and renal involvement in SLE. The RNASE1-based RAC score provides a noninvasive tool for improved disease assessment and may facilitate clinical monitoring and management of SLE patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.